StemCell Therapy

Freeport, Grand Bahama (PRWEB) December 18, 2014

Okyanos, the leader in cell therapy, announced the expansion of its medical team to accommodate the growing demand for cell therapy to treat patients with chronic unmet needs for which adult stem cell therapy using cells from a persons own fat (adipose) tissue has been found to be safe and efficacious. Led by a prestigious team of U.S.-licensed physicians and nursing staff, the team includes Dr. Todd Malan, Chief Cell Therapy Officer and pioneer of adipose-derived stem cell therapy, and is joined by Dr. Matthew Mick, Cardiologist, FACC, Fellowship at Cleveland Clinic.

We are very pleased to have such a competent and highly regarded aggregate of expertise, said Okyanos CEO Matt Feshbach. Our team is comprised of leaders in their respective fields, each of whom is committed to bringing about a new standard of care and better quality of life to our patients.

Todd Malan, MD, serves as the Chief Cell Therapy Officer and General Surgeon at Okyanos, overseeing the fat-harvesting and stem cell isolation step of the Okyanos cell therapy process. A pioneer of fat-derived stem cell therapies, he became the first physician in the U.S. to utilize stem cells from fat for soft tissue reconstruction in October 2009, combining water-assisted fat-harvesting, fat transfer and adult stem cell technologies.

Matthew J. Mick, MD, is a triple board-certified interventional cardiologist. After attending the Indiana University School of Medicine, Dr. Mick completed his Cardiovascular Disease and Interventional Fellowships at the Cleveland Clinic Foundation. Dr. Mick participated as Principal Investigator and Co-Investigator in more than 20 cardiac clinical trials. He was a leader in developing trans-radial cardiac catheterization and holds several patents for cardiac catheters. Dr. Mick has performed over 15,000 diagnostic procedures in his 22 years of practice.

As the Director of Nursing managing a medical team which now numbers 10, Gretchen Dezelick oversees all of the clinical operations and maintains the superior cleanliness and safety standards that help make Okyanos a center of excellence. With more than 25 years of nursing experience progressing from bedside nursing to administrative and management positions in a variety of healthcare settings, Gretchen was a Certified Critical Care Nurse (CCRN) for more than 20 years and has been a Certified Peri-Operative Nurse (CNOR) for more than three years as well as being a Licensed Health Care Risk Manager (LHCRM).

Okyanos is also very proud to include several Bahamian medical staff such as Anesthesiologist Dr. Vincent Burton, Fellow of the Royal College of Anaesthetists, UK (FRCA), a Certified Critical Care Nurse, cardiology tech, sonographer, surgical scrub tech and a facilities tech, to deliver well-rounded expert patient care. The team also includes a Certified Cardiovascular Nurse, a BSN RN and a cardiovascular tech, providing more than 88 years of combined experience.

Okyanos follows the treatment guidelines laid out in clinical trials such as PRECISE and others which have demonstrated positive results from adult stem cell therapy. Okyanos cell therapy is performed in their newly constructed surgery center built to U.S. surgical standards and which also includes a state-of-the-art Phillips cath lab.

Adult stem cell therapy has emerged as a new treatment alternative for those who are restricted in activities they can no longer do but are determined to live a more normal life. Okyanos cell therapy uses a unique blend of adult stem cells derived from a patients own fat tissue, thereby helping the bodys own natural biology to heal itself.

Just 50 miles from US shore, Okyanos cell therapy is available to patients with severe heart disease including coronary artery disease (CAD) and congestive heart failure (CHF) as well as patients with autoimmune diseases, tissue ischemia, neurological and orthopedic conditions.

Read more:
Okyanos Expands World-Class Cell Therapy Medical Team

This entry was posted on December 19, 2014 at 12:42 am and is filed under Cell Therapy. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |